{
    "clinical_study": {
        "@rank": "8320", 
        "arm_group": {
            "arm_group_label": "AMP-514", 
            "arm_group_type": "Experimental", 
            "description": "Escalating doses of AMP-514"
        }, 
        "brief_summary": {
            "textblock": "This is a multi-center, open-label, multi-dose, first-time-in-human study with a standard\n      3+3 dose-escalation phase in subjects with advanced solid malignancies."
        }, 
        "brief_title": "A Phase 1 Study to Evaluate AMP-514", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Solid Malignancies", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u226518 years of age at time of study entry\n\n          -  Written informed consent and any locally required authorization (eg, Health Insurance\n             Portability and Accountability Act [HIPAA]) obtained from the subject/legal\n             representative prior to performing any protocol-related procedures, including\n             screening evaluations\n\n          -  Life Expectancy of \u2265 12 weeks\n\n          -  Histologically- or cytologically-confirmed advanced solid tumor that is refractory to\n             standard therapy or for which no standard therapy exists\n\n          -  At least 1 measurable lesion per RECIST 1.1; subjects whose only measurable lesion is\n             a lymph node will be excluded\n\n          -  ECOG Performance Score of 0 or 1\n\n          -  Adequate organ and marrow function\n\n          -  Prior treatment toxicities must be \u2264 Grade 1\n\n          -  Willingness to provide consent for biopsy samples\n\n          -  Females of childbearing and unsterilized males must use 2 methods of effective\n             contraception from screening, and must agree to continue using such precautions for\n             90 days after the final dose of AMP-514\n\n        Exclusion Criteria:\n\n          -  Concurrent enrollment in another clinical study, unless it is an observational (non\n             interventional) clinical study or the follow-up period of an interventional study\n\n          -  Receipt of any immunotherapy, BRAF inhibitor (in metastatic melanoma), or\n             investigational anticancer therapy within 4 weeks prior to the first dose of AMP-514;\n             in the case of monoclonal antibodies, 6 weeks prior to the first dose of AMP-514\n\n          -  Prior exposure to any anti-PD-1 or anti-PD-L1 antibody\n\n          -  Any prior Grade \u22653 immune-related adverse event (irAE) while receiving immunotherapy\n             or any unresolved irAE > Grade 1\n\n          -  Major surgery (as defined by the investigator) within 4 weeks prior to first dose of\n             AMP-514 or still recovering from prior surgery\n\n          -  Other invasive malignancy within 2 years except for noninvasive malignancies such as\n             cervical carcinoma in situ, non-melanomatous carcinoma of the skin or ductal\n             carcinoma in situ of the breast that has/have been surgically cured\n\n          -  Prior allogeneic or autologous bone marrow or organ transplantation that requires use\n             of immunosuppressives\n\n          -  Unresolved toxicities from prior anticancer therapy, defined as having not resolved\n             to National Cancer Institute's (NCI's) Common Terminology Criteria for Adverse Events\n             (CTCAE) (NCI CTCAE v4.03) Grade 0 or 1, or to levels dictated in the\n             inclusion/exclusion criteria with the exception of alopecia. Subjects with\n             irreversible toxicity that is not reasonably expected to be exacerbated by AMP-514\n             may be included (eg, hearing loss) after consultation with the MedImmune medical\n             monitor.\n\n          -  Active or prior documented autoimmune disease within the past 2 years NOTE: Subjects\n             with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within\n             the past 2 years) are not excluded\n\n          -  History of primary immunodeficiency\n\n          -  Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer\n             treatment. Concurrent use of hormones for non-cancer-related conditions (eg, insulin\n             for diabetes and hormone replacement therapy) is acceptable.        NOTE: Local\n             treatment of isolated lesions for palliative intent is acceptable (eg, by local\n             surgery or radiotherapy)\n\n          -  Current or prior use of immunosuppressive medication within 28 days before the first\n             dose of AMP-514, with the exception of intranasal and inhaled corticosteroids or\n             systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone\n             or equivalent\n\n          -  Uncontrolled intercurrent illness\n\n          -  Symptomatic or untreated central nervous system metastases requiring concurrent\n             treatment\n\n          -  Known history of tuberculosis\n\n          -  Subjects who are known to be human immunodeficiency virus positive\n\n          -  Subjects who are known to be hepatitis B or C positive\n\n          -  Receipt of live attenuated vaccination within 30 days prior to study entry or within\n             30 days of receiving AMP-514\n\n          -  Pregnant or breastfeeding women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02013804", 
            "org_study_id": "AMP-514-01", 
            "secondary_id": "MEDI0680"
        }, 
        "intervention": {
            "arm_group_label": "AMP-514", 
            "description": "AMP-514 will be administered by IV infusion every 21 days", 
            "intervention_name": "AMP-514", 
            "intervention_type": "Drug", 
            "other_name": "MEDI0680"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Non-small cell lung cancer", 
            "Renal cell cancer", 
            "Colorectal cancer", 
            "Advanced malignant melanoma", 
            "Advanced cutaneous melanoma", 
            "Hepatocellular cancer", 
            "Squamous cell carcinoma of the head and neck", 
            "Gastroesophageal cancer", 
            "Triple negative breast cancer", 
            "Pancreatic adenocarcinoma", 
            "AMP-514", 
            "MEDI0680", 
            "Advanced solid tumors", 
            "PD-1", 
            "Anti PD-1", 
            "PD-L1", 
            "PD-L2"
        ], 
        "lastchanged_date": "December 18, 2013", 
        "location": {
            "contact": {
                "email": "amanda.mundy@scresearch.net", 
                "last_name": "Amanda Mundy", 
                "phone": "615-329-7274"
            }, 
            "facility": {
                "address": {
                    "city": "Nashville", 
                    "country": "United States", 
                    "state": "Tennessee", 
                    "zip": "37203"
                }, 
                "name": "Sarah Cannon Research Institute"
            }, 
            "investigator": {
                "last_name": "Jeffrey Infante, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Multi-Center, Open-label, Multi-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMP-514 in Subjects With Advanced Solid Malignancies", 
        "overall_official": {
            "affiliation": "Amplimmune", 
            "last_name": "Solomon Langermann, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Maximum tolerated dose (MTD) or optimal biological dose (OBD) will be determined by the number of subjects experiencing DLTs.  Safety profile will be assessed through the number of subjects experiencing AEs, SAEs, abnormal laboratory evaluations, vital signs, and physical examinations.", 
            "measure": "Number of subjects experiencing  dose-limiting toxicities (DLTs), adverse events (AEs), serious adverse events (SAEs)", 
            "safety_issue": "Yes", 
            "time_frame": "Through 90 days after last dose of AMP-514"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02013804"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "AMP-514 concentrations in serum and PK parameters including peak concentration, area under the concentration-time curve, clearance, and half-life.", 
                "measure": "Pharmacokinetic profile of AMP-514", 
                "safety_issue": "No", 
                "time_frame": "Through 90 days after the last dose of AMP-514"
            }, 
            {
                "description": "Disease status evaluated via RECIST 1.1.", 
                "measure": "Assess preliminary antitumor activity of AMP-514", 
                "safety_issue": "No", 
                "time_frame": "Approximately every 3 months through 12 months following last cycle of AMP-514"
            }, 
            {
                "description": "Includes assessment of receptor occupancy, reduction in PD-1 expression levels, and increase in T cells producing effector cytokines and lytic markers", 
                "measure": "Evaluate pharmacodynamic effects of AMP-514 on its target receptor, PD-1, as well as effects on immune system function", 
                "safety_issue": "No", 
                "time_frame": "Approximately every 3 months through 12 months following last cycle of AMP-514"
            }
        ], 
        "source": "Amplimmune", 
        "sponsors": {
            "collaborator": {
                "agency": "MedImmune LLC", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Amplimmune", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}